To access the full text documents, please follow this link: http://hdl.handle.net/2445/136657
dc.contributor | Universitat de Barcelona |
---|---|
dc.contributor.author | Zarei, Mohammad |
dc.contributor.author | Pujol Bech, Eugènia |
dc.contributor.author | Quesada López, Tania Paloma |
dc.contributor.author | Villarroya i Gombau, Francesc |
dc.contributor.author | Barroso Fernández, Emma |
dc.contributor.author | Vázquez Cruz, Santiago |
dc.contributor.author | Pizarro Delgado, Javier |
dc.contributor.author | Palomer Tarridas, Francesc Xavier |
dc.contributor.author | Vázquez Carrera, Manuel |
dc.date | 2019-07-08T09:23:27Z |
dc.date | 2019-03-30 |
dc.date | 2019-07-08T07:07:50Z |
dc.date | info:eu-repo/date/embargoEnd/2020-03-30 |
dc.identifier.citation | 0007-1188 |
dc.identifier.citation | 689598 |
dc.identifier.uri | http://hdl.handle.net/2445/136657 |
dc.format | 14 p. |
dc.format | application/pdf |
dc.language.iso | eng |
dc.publisher | Blackwell |
dc.relation | Versió postprint del document publicat a: https://doi.org/10.1111/bph.14678 |
dc.relation | British Journal of Pharmacology, 2019, vol. 176, num. 13, p. 2292-2305 |
dc.relation | https://doi.org/10.1111/bph.14678 |
dc.rights | (c) The British Pharmacological Society, 2019 |
dc.rights | info:eu-repo/semantics/embargoedAccess |
dc.subject | Malalties del fetge |
dc.subject | Diabetis |
dc.subject | Terapèutica |
dc.subject | Liver diseases |
dc.subject | Diabetes |
dc.subject | Therapeutics |
dc.title | Oral administration of a new HRI activator as a new strategy to improve high-fat-died-induced glucose intolerance, hepatic steatosis and hypertriglyceridemia through FGF21 |
dc.type | info:eu-repo/semantics/article |
dc.type | info:eu-repo/semantics/acceptedVersion |
dc.description.abstract |